Recent financial reports and strategic moves highlight dynamic changes in the biotech industry. Qiagen surpassed Q2 sales expectations with 7% revenue growth, driven by diagnostic solutions and next-generation sequencing, prompting an upward revision of their full-year guidance. Myriad Genetics plans to expand its hereditary cancer testing portfolio despite modest revenue growth. Notably, MDxHealth is acquiring Bio-Techne's Exosome Diagnostics for $15 million to enhance liquid biopsy offerings. Meanwhile, Bruker faces market challenges, implementing significant cost-cutting measures and lowering revenue guidance amidst organic sales decline.